Sage Group Plc jumped to a record high after the UK software company announced a share buyback plan of as much as £400 ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as ...

A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...

Hadba, Chief Product Officer at Sage Group plc, has increased his stake in the company by purchasing 1,750 ordinary shares at ...

Sage Publishing, a leading academic publisher, has acquired GOOD DOCS LLC, a film distribution company promoting social justice through powerful documentaries. This partnership adds over 370 films to ...

The Cambridge, Mass.-based company SAGE said it would give priority to the launch of zurzuvae, a treatment for postpartum depression, and focus on a study readout from its dalzanemdor as a ...

Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive ...

The Sage Group Plc engages in the provision of ... and North America. The company was founded by David Goldman, Paul Muller, and Graham Wylie in 1981 and is headquartered in Newcastle-upon-Tyne ...

Begin your TipRanks Premium journey today. SAGE Therapeutics (SAGE) Company Description: SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and ...

Sage Group shares jumped by a fifth to trade at a record high on Wednesday as the business software group hiked investor ...

Sage Group shares surge to a record high after better-than-expected earnings and a share buyback announcement.